<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ISOFLURANEÂ - isofluraneÂ liquidÂ </strong><br>Piramal Critical Care Inc<br></p></div>
<h1>Isoflurane USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Â Rx only</p>
<br><p>Isoflurane, USP, a nonflammable liquid administered by vaporizing, is a general inhalation anesthetic drug. <br>It is 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether, and its structural formula is:Â </p>
<div class="Figure"><img alt="iso-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d6851c71-0c2f-43f6-883c-a43fe894985d&amp;name=iso-structure.jpg"></div>
<p>Some physical constants are:Â Â  </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="border-collapse: collapse"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Molecular weight<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">184.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Boiling point at 760 mm Hg<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">48.5Â° C (uncorr.)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Refractive index <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">1.2990-1.3005<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Specific gravity 25Â°/25Â° C<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">1.496<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Vapor pressure in mm Hg**<br>
</td>
<td class="Rrule" valign="top">20Â° C<br>
</td>
<td class="Rrule" valign="top">238<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">25Â° C<br>
</td>
<td class="Rrule" valign="top">295<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">30Â° C<br>
</td>
<td class="Rrule" valign="top">367<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">35Â° C<br>
</td>
<td class="Rrule" valign="top">450<br>
</td>
</tr>
</tbody></table>
<br><br><p>Â Â Â Â Â Â Â Â </p>
<p>log<span class="Sub">10</span><span class="Italics">P<span class="Sub">vap</span></span>= A + B/TÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  </p>
<p>where:Â Â Â Â Â Â Â Â Â Â Â Â  <br></p>
<p>A = 8.056</p>
<p>B = -1664.58</p>
<p>T = Â°C + 273.16 (Kelvin)</p>
<br><p>Â Partition coefficients at 37Â°C:</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Water/gas<br>
</td>
<td class="Rrule" valign="top">0.61<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Blood/gas<br>
</td>
<td class="Rrule" valign="top">1.43<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Oil/gas<br>
</td>
<td class="Rrule" valign="top">90.8<br>
</td>
</tr>
</tbody></table>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" colspan="4" valign="top">Partition coefficients at 25Â° C - rubber and plastic<br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" colspan="2" valign="top">Conductive rubber/gas<br>
</td>
<td class="Rrule" valign="top">62.0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" colspan="2" valign="top">Butyl rubber/gas<br>
</td>
<td class="Rrule" valign="top">75.0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" colspan="2" valign="top">Polyvinyl chloride/gas<br>
</td>
<td class="Rrule" valign="top">110.0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" colspan="2" valign="top">Polyethylene/gas<br>
</td>
<td class="Rrule" valign="top">~2.0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" colspan="2" valign="top">Polyurethane/gas<br>
</td>
<td class="Rrule" valign="top">~1.4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" colspan="2" valign="top">Polyolefin/gas<br>
</td>
<td class="Rrule" valign="top">~1.1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" colspan="2" valign="top">Butyl acetate/gas<br>
</td>
<td class="Rrule" valign="top">~2.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">Purity by gas chromatography<br>
</td>
<td class="Rrule" colspan="2" valign="top">&gt;99.9%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">Lower limit of flammability in oxygen or<br>nitrous oxide at 9 joules/sec. and 23Â° C<br>
</td>
<td class="Rrule" colspan="2" valign="top">None<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" colspan="2" valign="top">Lower limit of flammability in oxygen or nitrous oxide at 900 joules/sec. and 23Â° C<br>
</td>
<td class="Rrule" colspan="2" valign="top">Greater than useful concentration in anesthesia.<br>
</td>
</tr>
</tbody></table>
<br><br><br><p>Isoflurane is a clear, colorless, stable liquid containing no additives or chemical stabilizers. Isoflurane has a mildly pungent, musty, ethereal odor. Samples stored in indirect sunlight in clear, colorless glass for five years, as well as samples directly exposed for 30 hours to a 2 amp, 115 volt, 60 cycle long wave U.V. light were unchanged in composition as determined by gas chromatography. Isoflurane in one normal sodium methoxide-methanol solution, a strong base, for over six months consumed essentially no alkali, indicative of strong base stability. Isoflurane does not decompose in the presence of soda lime (at normal operating temperatures), and does not attack aluminum, tin, brass, iron or copper.<br><br>Â Â </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Isoflurane, USP is an inhalation anesthetic. The MAC (minimum alveolar concentration) in man is as follows:</p>
<br><p>Â Â Â Â Â Â Â Â Â Â Â </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Age</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">100% Oxygen</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">70% N<span class="Sub">2</span>O</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">26Â±4<br>
</td>
<td class="Rrule" valign="top">1.28<br>
</td>
<td class="Rrule" valign="top">0.56<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">44Â±7<br>
</td>
<td class="Rrule" valign="top">1.15<br>
</td>
<td class="Rrule" valign="top">0.50<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">64Â±5<br>
</td>
<td class="Rrule" valign="top">1.05<br>
</td>
<td class="Rrule" valign="top">0.37<br>
</td>
</tr>
</tbody></table>
<br><br><p>Â Induction of and recovery from isoflurane anesthesia are rapid. Isoflurane has a mild pungency, which limits the rate of induction, although excessive <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> or tracheobronchial secretions do not appear to be stimulated. Pharyngeal and laryngeal reflexes are readily obtunded. The level of anesthesia may be changed rapidly with isoflurane. Isoflurane is a profound respiratory depressant. RESPIRATION MUST BE MONITORED CLOSELY AND SUPPORTED WHEN NECESSARY. As anesthetic dose is increased, tidal volume decreases and <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> is unchanged. This <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is partially reversed by surgical stimulation, even at deeper levels of anesthesia. Isoflurane evokes a sigh response reminiscent of that seen with diethyl ether and enflurane, although the frequency is less than with enflurane. Blood pressure decreases with induction of anesthesia but returns toward normal with surgical stimulation. Progressive increases in depth of anesthesia produce corresponding decreases in blood pressure. Nitrous oxide diminishes the inspiratory concentration of isoflurane required to reach a desired level of anesthesia and may reduce the arterial <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> seen with isoflurane alone. Heart rhythm is remarkably stable. With controlled ventilation and normal PaCO<span class="Sub">2</span>, <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> is maintained despite increasing depth of anesthesia, primarilyÂ through an increase in heart rate, which compensates for a reduction in <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>. The <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, which attends spontaneous ventilation during isoflurane anesthesia further increases heart rate and raises <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> above awake levels. Isoflurane does not sensitize the myocardium to exogenously administered epinephrine in the dog. Limited data indicate that subcutaneous injection of 0.25 mg of epinephrine (50 mL of 1:200,000 solution) does not produce an increase in <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> in patients anesthetized with isoflurane.<span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">Muscle relaxation</span> is often adequate for intra-abdominal operations at normal levels of anesthesia. Complete muscle <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> can be attained with small doses of muscle relaxants. ALL COMMONLY USED MUSCLE RELAXANTS ARE MARKEDLY POTENTIATED WITH ISOFLURANE, THE EFFECT BEING MOST PROFOUND WITH THE NONDEPOLARIZING TYPE. Neostigmine reverses the effect of nondepolarizing muscle relaxants in the presence of isoflurane. All commonly used muscle relaxants are compatible with isoflurane.Isoflurane can produce coronary vasodilation at the arteriolar level in selected animal models <span class="Sup">1,2</span>; the drug is probably also a coronary dilator in humans. Isoflurane, like some other coronary arteriolar dilators, has been shown to divert blood from collateral dependent myocardium to normally perfused areas in an animal model (â€œcoronary stealâ€?) <span class="Sup">3</span>.Clinical studies to date evaluating <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> as outcome parameters have not established that the coronary arteriolar dilation property of isoflurane is associated with coronary steal or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> <span class="Sup">4,5,6,7</span>.PharmacokineticsIsoflurane undergoes minimal biotransformation in man. In the postanesthesia period, only 0.17% of the isoflurane taken up can be recovered as urinary metabolites.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First">Isoflurane, USP may be used for induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Known sensitivity to Isoflurane, USP or to other halogenated agents. Known or suspected genetic susceptibility to <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Perioperative HyperkalemiaUse of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly <span class="product-label-link" type="condition" conceptid="4296473" conceptname="Duchenne muscular dystrophy">Duchenne muscular dystrophy</span>, appear to be most vulnerable.Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatinine kinase levels and, in some cases, changes in urine consistent with <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>. Despite the similarity in presentation to <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>, none of these patients exhibited signs or symptoms of <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> or hypermetabolic state. Early and aggressive intervention to treat the <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and resistant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> is recommended, as is subsequent evaluation for latent neuromuscular disease.Malignant HyperthermiaIn susceptible individuals, isoflurane anesthesia may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>. The syndrome includes nonspecific features such as <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and unstable blood pressure. (It should also be noted that many of these nonspecific signs may appear with <span class="product-label-link" type="condition" conceptid="4086497" conceptname="Light anesthesia">light anesthesia</span>, acute <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, etc.) An increase in overall metabolism may be reflected in an elevated temperature, (which may rise rapidly early or late in the case, but usually is not the first sign of augmented metabolism) and an increased usage of the CO<span class="Sub">2</span> absorption system (hot canister). PaO<span class="Sub">2</span> and pH may decrease, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and a base deficit mayÂ appear. Treatment includes discontinuance of triggering agents (e.g., isoflurane), administration of intravenous dantrolene sodium, and application of supportive therapy.Such therapy includes vigorous efforts to restore body temperature to normal, respiratory and circulatory support as indicated, and management of electrolyte-fluid-acid-base derangements. (Consult prescribing information for dantrolene sodium intravenous for additional information on patient management). <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> may appear later, and urine flow should be sustained if possible.Since levels of anesthesia may be altered easily and rapidly, only vaporizers producing predictable concentrations should be used. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> increase as anesthesia is deepened.Increased blood loss comparable to that seen with halothane has been observed in patients undergoing abortions. Isoflurane, USP markedly increases cerebral blood flow at deeper levels of anesthesia. There may be a transient rise in cerebral spinal fluid pressure, which is fully reversible with <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>General Precautions</h2>
<p class="First">As with any potent general anesthetic, Isoflurane, USP should only be administered in an adequately equipped anesthetizing environment by those who are familiar with the pharmacology of the drug and qualified by training and experience to manage the anesthetized patient.Regardless of the anesthetics employed, maintenance of normal hemodynamics is important to the avoidance of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> <span class="Sup">4,5,6,7</span>.Isoflurane, USP, like some other inhalational anesthetics, can react with desiccated <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> (CO<span class="Sub">2</span>) absorbents to produce <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">carbon monoxide</span>, which may result in elevated levels of <span class="product-label-link" type="condition" conceptid="4269049" conceptname="Carboxyhemoglobin">carboxyhemoglobin</span> in some patients. Case reports suggest that barium hydroxide lime and soda lime become desiccated when fresh gases are passed through the CO<span class="Sub">2</span> absorber canister at high flow rates over many hours or days. When a clinician suspectsÂ  that CO<span class="Sub">2</span> absorbent may be desiccated, it should be replaced before the administration of Isoflurane, USP. As with other halogenated anesthetic agents, Isoflurane, USP may cause sensitivity <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> in patients who have been sensitized by previous exposure to halogenated anesthetics (see <a href="#Section_4">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Isoflurane, as well as other general anesthetics, may cause a slight decrease in intellectual function for 2 or 3 days following anesthesia. As with other anesthetics, small changes in moods and symptoms may persist for up to 6 days after administration.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Transient increases in BSP retention, blood glucose and serum creatinine with decrease in BUN, serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and alkaline phosphatase have been observed.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_6.4"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<br><p class="First">Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N<span class="Sub">2</span>O. SeeÂ  <a href="#Section_2">CLINICAL PHARMACOLOGY</a>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_6.6"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis &amp; Mutagenesis &amp; Impairment Of Fertility</h2>
<p class="First">Swiss ICR mice were given isoflurane to determine whether such exposure might induce neoplasia. Isoflurane was given at Â½, 1/8 and 1/32 MAC for four in-utero exposures and for 24 exposures to the pups during the first nineÂ  weeks of life. The mice were killed at 15 months of age. The incidence of tumors in these mice was the same as in untreated control mice, which were given the same background gases, but not the anesthetic.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_6.7"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C</span>Isoflurane has been shown to have a possible anesthetic-related fetotoxic effect in mice when given in doses 6 times the human dose. There are no adequate and well-controlled studies in pregnant women. Isoflurane should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_6.9"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when isoflurane is administered to a nursing woman</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.12"></a><a name="section-6.8"></a><p></p>
<h2>SAFETY AND HANDLING</h2>
<p class="First">Occupational CautionThere is no specific work exposure limit established for Isoflurane, USP. However, the National Institute for Occupational Safety and Health Administration (NIOSH) recommends that no worker should be exposed at ceiling concentrations greater than 2 ppm of any halogenated anesthetic agent over a sampling period not to exceed one hour.The predicted effects of acute overexposure by inhalation of Isoflurane, USP include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or (in extreme cases) <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>. There are no documented adverse effects of chronic exposure to halogenated anesthetic vapors (Waste Anesthetic Gases or WAGs) in the workplace. Although results of some epidemiological studies suggest a link between exposure to halogenated anesthetics and increased health problems (particularly <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>), the relationship is not conclusive. Since exposure to WAGs is one possible factor in the findings for these studies, operating room personnel, and pregnant women in particular, should minimize exposure. Precautions include adequate general ventilation in the operating room, the use of a well-designed and well-maintained scavenging system, work practices to minimize leaks and spills while the anesthetic agent is in use, and routine equipment maintenance to minimize leaks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.13"></a><a name="section-6.9"></a><p></p>
<h2>HOW SUPPLIED</h2>
<p class="First">Storage</p>
<p>Store at room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [See USP Controlled Room Temperature]. </p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions encountered in the administration of Isoflurane, USP are in general dose dependent extensions of pharmacophysiologic effects and include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Shivering</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> have been observed in the postoperative period.As with all other general anesthetics, transient elevations in white blood count have been observed even in the absence of surgical stress. See <a href="#Section_5">WARNINGS</a> for information regarding <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> and elevated <span class="product-label-link" type="condition" conceptid="4269049" conceptname="Carboxyhemoglobin">carboxyhemoglobin</span> levels.During marketing, there have been rare reports of mild, moderate and severe (some fatal) postoperative hepatic dysfunction and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.Isoflurane USP has also been associated with perioperative <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (see <a href="#Section_5">WARNINGS</a>).There have been rare post-marketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> associated with the use of potent volatile anesthetic agents, including Isoflurane USP. Due to the spontaneous nature of these reports, the actual incidence and relationship of Isoflurane USP to these events cannot be established with certainty</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_9"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In the event of overdosage, or what may appear to be overdosage, the following action should be taken:Stop drug administration, establish a clear airway, and initiate assisted or controlled ventilation with pure oxygen.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First">PremedicationPremedication should be selected according to the need of the individual patient, taking into account that secretions are weakly stimulated by Isoflurane, USP, and the heart rate tends to be increased. The use of anticholinergic drugs is a matter of choice.Inspired ConcentrationThe concentration of isoflurane being delivered from a vaporizer during anesthesia should be known. This may be accomplished by using:a.Vaporizers calibrated specifically for isoflurane;b.Vaporizers from which delivered flows can be calculated, such as vaporizers delivering a saturated vapor, which is then diluted. The delivered concentration from such a vaporizer may be calculated using the formula:</p>
<br><br><p>% Isoflurane =Â  <span class="Underline">100 P<span class="Sub">V</span>F<span class="Sub">V</span></span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  F<span class="Sub">T</span> (P<span class="Sub">A</span> â€“ P<span class="Sub">V</span>)</p>
<br><p>where:Â Â Â Â Â Â Â Â Â Â Â Â  P<span class="Sub">A</span> = Pressure of atmosphere </p>
<p>P<span class="Sub">V</span> = Vapor pressure of isoflurane</p>
<p>F<span class="Sub">V</span> = Flow of gas through vaporizer (mL/min)</p>
<p>F<span class="Sub">T</span> = Total gas flow (mL/min)</p>
<br><p>Isoflurane contains no stabilizer. Nothing in the drug product alters calibration or operation of these vaporizers.</p>
<br><p>InductionInduction with isoflurane in oxygen or in combination with oxygen-nitrous oxide mixtures may produce <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4233530" conceptname="Interrupted breathing">breath holding</span>, or <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>. These difficulties may be avoided by the use of a hypnotic dose of an ultra-short-acting barbiturate. Inspired concentrations of 1.5 to 3.0% isoflurane usually produce surgical anesthesia in 7 to 10 minutes.MaintenanceSurgical levels of anesthesia may be sustained with a 1.0 to 2.5% concentration when nitrous oxide is used concomitantly. An additional 0.5 to 1.0% may be required when isoflurane is given using oxygen alone. If added relaxation is required, supplemental doses of muscle relaxants may be used.The level of blood pressure during maintenance is an inverse function of isoflurane concentration in the absence of other complicating problems. Excessive decreases may be due to depth of anesthesia and in such instances may be corrected by lightening anesthesia.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Isoflurane, USP is packaged in 100 mL and 250 mL amber-colored bottles.250 ml NDC 66794-017-25<br>100 mL NDC 66794-017-10</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_14"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1. J.C. Sill, et al, Anesthesiology 66:273-279, 19872. R.F. Hickey, et al, Anesthesiology 68:21-30, 19883. C.W. Buffington, et al, Anesthesiology 66:280-292, 19874. S. Reiz, et al, Anesthesiology 59:91-97, 19835. S. Slogoff and A.S. Keats, Anesthesiology 70:179-188, 19896. K.J. Tuman, et al, Anesthesiology 70:189-198, 19897. D.T. Mangano, Editorial Views, Anesthesiology 70:175-178, 1989</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_4"></a><a name="section-12"></a><p></p>
<h1>MANUFACTURED BY</h1>
<p class="First">PiramalÂ Enterprises LimitedN.H. 9, Digwal Village, Kohir Mandal,Kohir Cross Road, Medak Dist. 502 321 Andhra Pradesh, India</p>
<p>Revised: May 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-13"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-100ml</h1>
<div class="Figure"><img alt="label100" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d6851c71-0c2f-43f6-883c-a43fe894985d&amp;name=pccisohum100.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Unclassified_Section_20"></a><a name="section-14"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-250ml</h1>
<div class="Figure"><img alt="label250" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d6851c71-0c2f-43f6-883c-a43fe894985d&amp;name=pccisohum250.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ISOFLURANEÂ 		
					</strong><br><span class="contentTableReg">isoflurane liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66794-017</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOFLURANE</strong> (ISOFLURANE) </td>
<td class="formItem">ISOFLURANE</td>
<td class="formItem">1Â mL Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66794-017-10</td>
<td class="formItem">100 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:66794-017-25</td>
<td class="formItem">250 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074502</td>
<td class="formItem">10/07/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Piramal Critical Care Inc
							(805600439)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Piramal Enterprises Limited</td>
<td class="formItem"></td>
<td class="formItem">919067108</td>
<td class="formItem">ANALYSIS(66794-017), API MANUFACTURE(66794-017), MANUFACTURE(66794-017), PACK(66794-017)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5a8c59b2-59ea-441f-99ef-ddea13a6acd6</div>
<div>Set id: d6851c71-0c2f-43f6-883c-a43fe894985d</div>
<div>Version: 8</div>
<div>Effective Time: 20150105</div>
</div>
</div>Â <div class="DistributorName">Piramal Critical Care Inc</div></p>
</body></html>
